肺癌的免疫治疗临床研究进展  

Review on Immunotherapies for Lung Cancer

作　　者：金莎[1] 田建辉[2] 

机构地区：[1]上海中医药大学 [2]上海中医药大学附属龙华医院肿瘤科,上海200032

出　　处：《中国肺癌杂志》2012年第10期606-611,共6页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金(No.81173224);上海市科学技术委员会(No.11ZR1437000);上海中医药大学附属龙华医院龙医学者项目(No.LHSD-11)资助~~

摘　　要：肺癌是一种恶性程度很高、早期发现率低且预后很差的恶性肿瘤,迫切需要开发更有效的治疗方法和药物。随着对肿瘤免疫发生和免疫耐受认识的不断深入,肺癌的免疫治疗进展很快,早期临床研究初步确认了依普利单抗、程序性死亡受体抗体(programmed death-1,PD-1)、Toll样受体拮抗剂、BLP25脂质体疫苗、Belagenpumatucel-L、黑色素瘤相关抗原A3(melanoma-associated antigen A3,MAGE-A3)蛋白疫苗和乳铁蛋白等对肺癌的治疗有效性,多数已进入Ⅲ期临床研究阶段,有望获得更有力的证据而最终成为肺癌综合治疗的重要组成部分。肺癌免疫治疗疗效提高面临的问题有目标人群的选择、免疫耐受的克服(包括免疫逃逸和免疫衰老)、免疫治疗疗效标准的制订等。Lung cancer is a highly malignant disease with poor prognosis, most cases are diagnosed at a very late stage. More effective medications or therapies should be developed to improve its prognosis. The advancement of tumor im- munity and tumor immunosuppression facilitated the feasibility of immunotherapies for lung cancer. Ipilimumab, antibody to Programmed death-1 （PD-1）, Toll-like receptor agonists, liposomal BLP25 （L- BLP25）, belagenpumatucel-L, melanoma-asso- ciated antigen A3 （MAGE-A3） vaccine and talactoferrin have been proved to be effective for lung cancer through early clinical trials, most of the drugs have moved forward to phase III trials, so as to collect much higher level evidence to support the im- munotherapies incorporated into the multidisciplinary treatment of lung cancer. The selection of target patients at appropriate stages, breaking down of tumor immunosuppression as well as the objective measurement of tumor response to the therapy are major challenges for the development of immunotherapies for lung cancer. The clarifying of the mechanism of immune escape led to the above drug development, and immune-senescence has already become the hotspot in this field.

关 键 词：肺肿瘤 主动免疫治疗 被动免疫 免疫逃逸 

分 类 号：R734.2[医药卫生—肿瘤]